Entinostat (MS-275)

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 24900.00
JPY 44820.00
JPY 127820.00

文献中の使用例(62)

カスタマーフィードバック(14)

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NF3RPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LFbGlEPTB;MD6wOlEh|ryP M{O5d3NCVkeHUh?=
ALL-PO NE\Yc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF22XZRKSzVyPUCuNFY{PTVizszN NIL5N21USU6JRWK=
697 NFzKfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEm5O|Yh|ryP NHv0VnpUSU6JRWK=
NCI-H748 NHm2U5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfsfoxQUUN3ME2wMlExOzN2IN88US=> MWXTRW5ITVJ?
NKM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn22TWM2OD1yLkGwPVEzKM7:TR?= NGGze|JUSU6JRWK=
ES1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfPTWM2OD1yLkGxNlU2KM7:TR?= M3fKOXNCVkeHUh?=
NCI-H1963 NFfxc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjYSHdiUUN3ME2wMlEyPTd7IN88US=> MXrTRW5ITVJ?
NCI-H1417 NFi2cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMUK5O|Qh|ryP M1rIfXNCVkeHUh?=
NEC8 NIP0d|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMUO1Nlch|ryP NUjyWoM5W0GQR1XS
CRO-AP2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TWTGlEPTB;MD6xOlg5QSEQvF2= MVPTRW5ITVJ?
A3-KAW NITWcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\hTWM2OD1yLkG3OlI4KM7:TR?= NXjyU3RKW0GQR1XS
SF539 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXjNodKSzVyPUCuNVk2QTNizszN MUPTRW5ITVJ?
NOS-1 M4Hsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDtUotKSzVyPUCuNVk3OTlizszN Mm\MV2FPT0WU
NTERA-S-cl-D1 NGfRenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMkCxNVMh|ryP NYnMblRoW0GQR1XS
COR-L88 NID1XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMkK5OVkh|ryP NXj5NXZsW0GQR1XS
EM-2 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe1SpRPUUN3ME2wMlI1ODd7IN88US=> Mn[1V2FPT0WU
KARPAS-45 MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonGTWM2OD1yLkK3PFM{KM7:TR?= M4SyTHNCVkeHUh?=
DSH1 M3Lvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLxTWM2OD1yLkK4O|A5KM7:TR?= NW\aTY57W0GQR1XS
HT-144 NGTVZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[yOmlEPTB;MD6zNFI2PiEQvF2= MoPZV2FPT0WU
ATN-1 NXvLbHRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDmZpU5UUN3ME2wMlMxPTd4IN88US=> NVLIboFbW0GQR1XS
HEL NV:zN5JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTBwM{GzOFgh|ryP M1HuOnNCVkeHUh?=
NB12 M3LBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTjTWM2OD1yLkOxO|U3KM7:TR?= NVzPU5J4W0GQR1XS
LU-139 NXrId211T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3u[3dxUUN3ME2wMlM{PTFizszN M3\PUnNCVkeHUh?=
J-RT3-T3-5 MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\iZWlEPTB;MD6zN|cyPiEQvF2= NIP0OYNUSU6JRWK=
MOLT-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWTWM2OD1yLkOzPFEh|ryP NH;LWGZUSU6JRWK=
SR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KyWGlEPTB;MD6zOFI3OSEQvF2= NFqyW2tUSU6JRWK=
CMK NHn1clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWW1VWloUUN3ME2wMlM2PzJ5IN88US=> NV34OlcyW0GQR1XS
ES8 NH3UOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwM{[wNlIh|ryP M2iye3NCVkeHUh?=
LB647-SCLC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ZNWNKSzVyPUCuN|Y4OyEQvF2= MkHtV2FPT0WU
TE-8 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmdGlEPTB;MD6zOlk{PSEQvF2= MV;TRW5ITVJ?
BV-173 NVziWWRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u4N2lEPTB;MD6zO|EzOSEQvF2= M4nXS3NCVkeHUh?=
DEL MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LEOGlEPTB;MD6zO|Q5PyEQvF2= MlzvV2FPT0WU
ARH-77 NGjPTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwM{ixPVMh|ryP NHn1NodUSU6JRWK=
NCCIT Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwM{i2OFkh|ryP NV\QVXpuW0GQR1XS
RPMI-8402 NIfvdHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLq[pVDUUN3ME2wMlM5PzBzIN88US=> MWjTRW5ITVJ?
MONO-MAC-6 MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDYTWM2OD1yLkO4O|c3KM7:TR?= MkG5V2FPT0WU
SK-MM-2 NHzOSGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXXTWM2OD1yLkO5PFY5KM7:TR?= NF3ld45USU6JRWK=
CHP-126 NHvnXGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC5TWM2OD1yLkSwNlMyKM7:TR?= MUjTRW5ITVJ?
A101D MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT1W4RKSzVyPUCuOFA{KM7:TR?= NHPmPHRUSU6JRWK=
SCH NW\qU5l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jKN2lEPTB;MD60NFM1OiEQvF2= M1HGcnNCVkeHUh?=
NMC-G1 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwNECzOlch|ryP NUf1fmRQW0GQR1XS
NCI-H209 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwNEC2NVMh|ryP M3e1O3NCVkeHUh?=
MOLT-16 NHK4XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPhd|dKSzVyPUCuOFExOTdizszN NYHsV25nW0GQR1XS
RPMI-6666 NEXvRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PUZWlEPTB;MD60NVEzKM7:TR?= MWDTRW5ITVJ?
OPM-2 NHzX[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELpV|hKSzVyPUCuOFE2OTNizszN NX;PNlBoW0GQR1XS
MRK-nu-1 NWfkZ2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjEV3VKSzVyPUCuOFMyPTNizszN NYfFVZU1W0GQR1XS
BC-1 M4XKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNEO0NFMh|ryP MlW2V2FPT0WU
MHH-NB-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnOxTWM2OD1yLkSzOFU{KM7:TR?= M4Xue3NCVkeHUh?=
Ramos-2G6-4C10 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGL5RVdKSzVyPUCuOFM5QTdizszN NXLac5dNW0GQR1XS
LS-513 M1Hsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fH[GlEPTB;MD60OFUxOSEQvF2= MYXTRW5ITVJ?
K5 M{\WXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWruXJk2UUN3ME2wMlQ4ODJ3IN88US=> NYD6NYl6W0GQR1XS
HOP-62 NEXX[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;qTWM2OD1yLkS4N|U5KM7:TR?= MVHTRW5ITVJ?
NCI-H187 M3XRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nqbWlEPTB;MD60PVIzPyEQvF2= M1r0WnNCVkeHUh?=
BE-13 NULHTnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjwTWM2OD1yLkS5OlYyKM7:TR?= MYnTRW5ITVJ?
HC-1 NXjoZZN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwNUC0O|Mh|ryP MW\TRW5ITVJ?
ACN MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDGcYhKSzVyPUCuOVExOjhizszN MYnTRW5ITVJ?
HCC1599 NF;nb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHlTWM2OD1yLkWxOVch|ryP MVLTRW5ITVJ?
MV-4-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHYW|R[UUN3ME2wMlU{ODRzIN88US=> NIT1dXRUSU6JRWK=
LC-2-ad MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNUO2OlMh|ryP M{fVe3NCVkeHUh?=
HL-60 M{DCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHkTWM2OD1yLkW0NlYyKM7:TR?= NIH1NJlUSU6JRWK=
NB17 Mk\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2WId[UUN3ME2wMlU1OzhizszN NY[1TnB5W0GQR1XS
TE-1 M{\NdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjyc2lVUUN3ME2wMlU2OzB4IN88US=> NXnXUo5RW0GQR1XS
NCI-H524 NVfVXoZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\PZpZkUUN3ME2wMlU2PDBzIN88US=> NYXLPJY1W0GQR1XS
MZ7-mel MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonyTWM2OD1yLkW2NVA2KM7:TR?= M2LBNnNCVkeHUh?=
L-363 NIjKO3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj2TWM2OD1yLkW2OlU4KM7:TR?= MnGzV2FPT0WU
BL-41 NV21dWR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLCTWM2OD1yLkW2PFg6KM7:TR?= M{\E[XNCVkeHUh?=
LU-134-A NGPpOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwNUewO|Mh|ryP MX;TRW5ITVJ?
SIG-M5 NITGWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlv4TWM2OD1yLkW3PFQ5KM7:TR?= M4TV[HNCVkeHUh?=
ONS-76 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTkTWM2OD1yLkW4NlQzKM7:TR?= NFzScZRUSU6JRWK=
KARPAS-299 NYfRTGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXLd3ZKSzVyPUCuOVg2ODRizszN M4m4W3NCVkeHUh?=
DU-4475 M2LRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYW2TWNGUUN3ME2wMlU5PzB|IN88US=> NU\IWXhLW0GQR1XS
NB69 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwNUm4NlUh|ryP Ml\nV2FPT0WU
MHH-PREB-1 M3LPSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj5UVBKSzVyPUCuOlA4OTlizszN Mlj2V2FPT0WU
LU-165 M3n4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjFTWM2OD1yLk[xPFEzKM7:TR?= NXjLeGYxW0GQR1XS
LOUCY MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmyTWM2OD1yLk[zN|Y1KM7:TR?= NU\xbWNYW0GQR1XS
NCI-H526 M17ZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwNkO1OFEh|ryP NHe2OJlUSU6JRWK=
KE-37 M3;wN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwNkSyO|Yh|ryP M4\aZ3NCVkeHUh?=
NALM-6 M13TWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPmWGUxUUN3ME2wMlY1QDZizszN M{e2Z3NCVkeHUh?=
CW-2 MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXJXIM6UUN3ME2wMlY2Pzl2IN88US=> NGXGRWJUSU6JRWK=
SU-DHL-1 NGnES|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHWTWM2OD1yLk[1PVQ4KM7:TR?= NWfxdnpMW0GQR1XS
NB13 M4W3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfKTWM2OD1yLk[2PFE4KM7:TR?= MnS4V2FPT0WU
QIMR-WIL NUXqSIkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm1d4RKSzVyPUCuOlg{PDNizszN M2PEVnNCVkeHUh?=
ECC12 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDCTWM2OD1yLkewNFg3KM7:TR?= MVPTRW5ITVJ?
KALS-1 NH;p[nNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjkfXZKSzVyPUCuO|A1QTJizszN M{jkTnNCVkeHUh?=
COR-L279 M4mzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f1SGlEPTB;MD63NFk6PiEQvF2= NGDFTWRUSU6JRWK=
NB14 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr6N|gzUUN3ME2wMlczPjF5IN88US=> M1v0XHNCVkeHUh?=
CCRF-CEM NX71[5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\OUWlEPTB;MD63OFY3OSEQvF2= MoriV2FPT0WU
SW954 M4jROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5NlJKSzVyPUCuO|U6QTlizszN M4Ha[3NCVkeHUh?=
IST-SL1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4VW9pUUN3ME2wMlc4OzR6IN88US=> NV[0So1zW0GQR1XS
LAMA-84 NXftcpYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwN{e1Olch|ryP Mn\RV2FPT0WU
Daudi NHXKb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nufGlEPTB;MD63O|Y5OSEQvF2= M3G0bHNCVkeHUh?=
BC-3 NIn2NW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwN{izNFgh|ryP M4fnVXNCVkeHUh?=
HCC2998 NWH3Nmc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzKPJhKSzVyPUCuO|g{PiEQvF2= NHvHclhUSU6JRWK=
NCI-H69 MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Pr[mlEPTB;MD64NFE1PyEQvF2= MXTTRW5ITVJ?
CPC-N NFyyOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLme3FKSzVyPUCuPFA2OjRizszN NHWycm5USU6JRWK=
NOMO-1 MkDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP1TWM2OD1yLkixNFg1KM7:TR?= MWfTRW5ITVJ?
CESS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwOEGxPVch|ryP MXHTRW5ITVJ?
LC4-1 NWm1UVFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwOESwNFch|ryP NUTmPYZRW0GQR1XS
BL-70 MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwOEW3NFIh|ryP MXvTRW5ITVJ?
ES4 NF7ycWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1yLki1PFY5KM7:TR?= MnL0V2FPT0WU
HCE-T MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTrSXJKSzVyPUCuPFcyPzFizszN NXPFOXNOW0GQR1XS
JAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrUWFRKSzVyPUCuPFc5OjdizszN MXfTRW5ITVJ?
ST486 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHToNndKSzVyPUCuPFc6OTdizszN MmTQV2FPT0WU
KS-1 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD1yLki4NFk3KM7:TR?= MW\TRW5ITVJ?
GDM-1 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXo[pV1UUN3ME2wMlg5Pjh5IN88US=> MV\TRW5ITVJ?
EHEB MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwOUK1PFUh|ryP NEfReZdUSU6JRWK=
LB2518-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO5dYRSUUN3ME2wMlk{Ojh2IN88US=> NYfSeHl4W0GQR1XS
GOTO NHXKWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwOUWwO|Yh|ryP NUXmbHFTW0GQR1XS
LXF-289 NH3yeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwOUW5NFEh|ryP Mon2V2FPT0WU
ES6 NFO5WXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWCxcnMyUUN3ME2wMlk3PDN5IN88US=> MYnTRW5ITVJ?
OS-RC-2 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwOU[4N{DPxE1? MmnyV2FPT0WU
DMS-153 M2roOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUe0Olkh|ryP MUPTRW5ITVJ?
SK-PN-DW MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\N[GlEPTB;MD65O|g{OSEQvF2= NXfwTHJiW0GQR1XS
HH M37Lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PDR2lEPTB;MD65PFk2QSEQvF2= MXHTRW5ITVJ?
SH-4 NHzVVndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID4NZBKSzVyPUGuNFI1OSEQvF2= MWjTRW5ITVJ?
MOLT-4 M3\hbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLZOWxLUUN3ME2xMlA{PDV2IN88US=> NHji[4NUSU6JRWK=
TGW MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H0TGlEPTB;MT6wO|Y4PSEQvF2= M{XVZnNCVkeHUh?=
L-540 NVTMTnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMUC2NFQh|ryP NHG1NGpUSU6JRWK=
PF-382 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDTVoYxUUN3ME2xMlEyPTF|IN88US=> Ml\PV2FPT0WU
LC-1F MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LkTWlEPTB;MT6xNlAxPyEQvF2= NFz2UWxUSU6JRWK=
OVCAR-4 NULCSYFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fKb2lEPTB;MT6xN|E3PSEQvF2= MmroV2FPT0WU
A4-Fuk MoXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjGXGlQUUN3ME2xMlE2OzZ2IN88US=> MUHTRW5ITVJ?
HCC2218 NIfWemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTFwMU[2OFEh|ryP MY\TRW5ITVJ?
HAL-01 M2nyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Pnb2lEPTB;MT6xOlk1OyEQvF2= MlzMV2FPT0WU
IST-MEL1 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW0ZmQ{UUN3ME2xMlE4PjV7IN88US=> MmjDV2FPT0WU
NCI-H719 NFWyVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PXUWlEPTB;MT6xO|g6QCEQvF2= NWHvNGJNW0GQR1XS
EVSA-T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2yTWM2OD1zLkG4NVE1KM7:TR?= NWrLOVJUW0GQR1XS
SK-NEP-1 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoniTWM2OD1zLkKwNlY3KM7:TR?= M33UXXNCVkeHUh?=
OCUB-M NW\WeoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP6VmFKSzVyPUGuNlE1QDlizszN Ml;XV2FPT0WU
MEG-01 M{Tle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPXTWM2OD1zLkKyNVE5KM7:TR?= NY\wUFlsW0GQR1XS
no-10 NVn6[W5FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3qVoVKSzVyPUGuNlMyOTJizszN NGHNZ21USU6JRWK=
MHH-CALL-2 M1;DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;oTWM2OD1zLkK0O|IyKM7:TR?= M1S0XHNCVkeHUh?=
SK-N-DZ Ml7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjW[mR[UUN3ME2xMlI1Pzd4IN88US=> MnT1V2FPT0WU
SCLC-21H M3jVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17NeGlEPTB;MT6yOlQ4QCEQvF2= NXvqZpRNW0GQR1XS
CTV-1 M2TOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M136OWlEPTB;MT6yO|QzPSEQvF2= Mm[4V2FPT0WU
NB1 M3nmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf1XItzUUN3ME2xMlI4PzN{IN88US=> MV;TRW5ITVJ?
NCI-H64 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfrd|A1UUN3ME2xMlI5PDZ{IN88US=> M134dXNCVkeHUh?=
MDA-MB-134-VI MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwMki1O|ch|ryP M4ToVHNCVkeHUh?=
LB2241-RCC NI\6XpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFOwV4dKSzVyPUGuNlg3PjNizszN NF\VVnBUSU6JRWK=
8-MG-BA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS0bHlKSzVyPUGuNlg5PjZizszN NUCzdmV[W0GQR1XS
LP-1 M3XHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fUTWlEPTB;MT6yPVk1PyEQvF2= NELkSGVUSU6JRWK=
LS-411N M1rzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD4TWM2OD1zLkOwPVk5KM7:TR?= M2O4THNCVkeHUh?=
CAL-148 NEnJVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGG4WpdKSzVyPUGuN|I2PDJizszN MUPTRW5ITVJ?
NCI-H2171 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFe1OHFKSzVyPUGuN|Q2ODJizszN M2nlfXNCVkeHUh?=
JiyoyeP-2003 M1W2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnMTXlKSzVyPUGuN|U{QSEQvF2= NV:zfYVKW0GQR1XS
NCI-H2107 NWfnb4FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO4ZWo4UUN3ME2xMlM2QDh|IN88US=> NFrt[5JUSU6JRWK=
BB30-HNC M3\Ee2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjmTWM2OD1zLkO4PVc5KM7:TR?= MnjPV2FPT0WU
K-562 NXPjZVIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFwM{myNVkh|ryP MnnTV2FPT0WU
PSN1 NUizSZpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\Sd|NKSzVyPUGuOFIzQDdizszN NWnsPWd2W0GQR1XS
HCC2157 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJU5V[UUN3ME2xMlQzPjlzIN88US=> Mo[wV2FPT0WU
SBC-1 NFPqfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofhTWM2OD1zLkSyO|QyKM7:TR?= MXnTRW5ITVJ?
MC116 NFTEOFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTFwNEO2NVUh|ryP NEnibmpUSU6JRWK=
KARPAS-422 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDXO21KSzVyPUGuOFU{PThizszN Ml:wV2FPT0WU
LB996-RCC M3PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLqTWM2OD1zLkS3NVA{KM7:TR?= MVXTRW5ITVJ?
MSTO-211H NIf6[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTFwNEe5PFch|ryP MWrTRW5ITVJ?
BT-474 NILTcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrXSIJ2UUN3ME2xMlUyPzZ2IN88US=> MmrQV2FPT0WU
A388 NGfwbXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmiyTWM2OD1zLkWxPVQ2KM7:TR?= MWDTRW5ITVJ?
SJSA-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzwT4hbUUN3ME2xMlUzOjZizszN MYfTRW5ITVJ?
COLO-829 M4XHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwNUO1OlQh|ryP NYD4dIJVW0GQR1XS
KM-H2 NFHlNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHH5bGhKSzVyPUGuOVY3PyEQvF2= MonGV2FPT0WU
GR-ST MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkP0TWM2OD1zLkW2PFIh|ryP MU\TRW5ITVJ?
RPMI-8866 NXLJV4dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWzS5RJUUN3ME2xMlYxOTR2IN88US=> NYC3TlBvW0GQR1XS
KG-1 MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfke3J1UUN3ME2xMlYyQTBzIN88US=> MV3TRW5ITVJ?
NCI-H82 M{P6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\0OnI5UUN3ME2xMlY{PDB4IN88US=> MYDTRW5ITVJ?
LB1047-RCC MkOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\FTJl6UUN3ME2xMlY{PDV7IN88US=> MmP5V2FPT0WU
KM12 MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDvUmdKSzVyPUGuOlQ4KM7:TR?= NGeyOnlUSU6JRWK=
NB5 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C2TmlEPTB;MT62OVY4PyEQvF2= NHLteZFUSU6JRWK=
HDLM-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\IW3hKSzVyPUGuOlgzQDFizszN NYH2SHFnW0GQR1XS
KU812 NVvUe3VGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwNkm2NFUh|ryP NH7CUGRUSU6JRWK=
DB MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfONZZMUUN3ME2xMlcxOzV|IN88US=> NGTXToJUSU6JRWK=
HD-MY-Z NVnwO5QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwN{WyN|Qh|ryP M3nxZ3NCVkeHUh?=
KURAMOCHI NYC0eHozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[weGlEPTB;MT63O|IxPyEQvF2= M3TjenNCVkeHUh?=
ETK-1 MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwN{i4O|kh|ryP NYTYT4QxW0GQR1XS
SK-UT-1 NEDL[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2f5eGlEPTB;MT63PVM5QCEQvF2= MYfTRW5ITVJ?
HUTU-80 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PMRWlEPTB;MT63PVUxQCEQvF2= M4f5NHNCVkeHUh?=
ES7 NWDnRnlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoK3TWM2OD1zLkiwN|AzKM7:TR?= MlHKV2FPT0WU
SW872 M2S1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn4fWRKSzVyPUGuPFE{QTVizszN M3rKdnNCVkeHUh?=
TK10 M4fLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpT|dKSzVyPUGuPFMyODhizszN Ml74V2FPT0WU
LB831-BLC MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFixWoFKSzVyPUGuPFM2PjNizszN Mn75V2FPT0WU
TE-9 M37wSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTsb|ZKSzVyPUGuPFQ1OjJizszN NUC4Z5FOW0GQR1XS
MLMA NUnOeFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3kSIdyUUN3ME2xMlg5OjN2IN88US=> Mo[1V2FPT0WU
D-542MG MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTjTWM2OD1zLki5N|c{KM7:TR?= NVnlXXB[W0GQR1XS
EW-16 MnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwOUK3NkDPxE1? NYXVN5dHW0GQR1XS
LOXIMVI Mke4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwOUOyPEDPxE1? NIL6dFZUSU6JRWK=
GB-1 NV2wNGw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjXe5lKSzVyPUGuPVM5PjZizszN NH\wZm1USU6JRWK=
IST-SL2 NUK2N2FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwMECyOlIh|ryP NILXO4ZUSU6JRWK=
LAN-6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1viZWlEPTB;Mj6wNVk3PiEQvF2= MVPTRW5ITVJ?
NCI-H510A MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXjTWM2OD1{LkC0OVAzKM7:TR?= NHPXTHlUSU6JRWK=
NCI-H1092 M4jnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTpR|ZqUUN3ME2yMlA2OTJ2IN88US=> MVrTRW5ITVJ?
HT NETaSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Eb49oUUN3ME2yMlExPDV2IN88US=> MoP6V2FPT0WU
RL95-2 M4qzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDCfYNHUUN3ME2yMlEyPDh{IN88US=> MkHOV2FPT0WU
NCI-H1355 NWTYcmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe4clV5UUN3ME2yMlEyPzl{IN88US=> MVfTRW5ITVJ?
NCI-H720 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDO3F2UUN3ME2yMlE3QDd|IN88US=> MkDhV2FPT0WU
NCI-H1522 NWS5UnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjh[npKSzVyPUKuNlE4OjNizszN MlnMV2FPT0WU
LB373-MEL-D MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3H5[2lEPTB;Mj6yOlkxOiEQvF2= MWHTRW5ITVJ?
DG-75 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vRfGlEPTB;Mj6yO|E1QCEQvF2= NWnWVFBsW0GQR1XS
ML-2 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwM{K4OVUh|ryP NGjCV4NUSU6JRWK=
SF126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LmRmlEPTB;Mj6zN|A6PCEQvF2= NHzuVGZUSU6JRWK=
MPP-89 NFzBd|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XtVWlEPTB;Mj6zN|E1PSEQvF2= MWTTRW5ITVJ?
NCI-H345 NF6xSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XBXGlEPTB;Mj6zN|I4PyEQvF2= MmnaV2FPT0WU
LS-123 NGnw[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTTPYVKSzVyPUKuN|Q6OzZizszN NVfWW2V3W0GQR1XS
NB10 NF7OboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJwNEGwPVIh|ryP MkfkV2FPT0WU
CGTH-W-1 NV63cnlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:0VGlEPTB;Mj60NlI3PyEQvF2= MlW2V2FPT0WU
CP66-MEL NVzXVpcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOyfotKSzVyPUKuOFc4PyEQvF2= M1XjVnNCVkeHUh?=
L-428 NHPlTVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7LTWM2OD1{LkS4OVIyKM7:TR?= NFHGd4VUSU6JRWK=
DMS-79 M1PGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfRbXlKSzVyPUKuOVQyODNizszN MWTTRW5ITVJ?
NCI-H1882 M2fHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwNke1OlIh|ryP MoPhV2FPT0WU
KGN M4LzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTkW4RuUUN3ME2yMlc3QDd4IN88US=> MmnJV2FPT0WU
EW-1 M1LDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwN{ewPFMh|ryP NU\m[I9oW0GQR1XS
U-266 M2myUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILDW2VKSzVyPUKuPFQ5OjNizszN NEHDZXNUSU6JRWK=
COLO-320-HSR NGP2UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm0[VVKSzVyPUKuPFU3PDFizszN MWPTRW5ITVJ?
KMOE-2 MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi2S4NKSzVyPUKuPFc4OTFizszN NX7kelJKW0GQR1XS
BB49-HNC M3XWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJwOUK0PEDPxE1? NFe1dm5USU6JRWK=
GI-1 NF;aT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr0ToFCUUN3ME2yMlkzQTV5IN88US=> NXjre21WW0GQR1XS
NCI-H1304 NGD4fHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMEC1NVEh|ryP MWrTRW5ITVJ?
NCI-H2227 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNwMEKwO|kh|ryP MoK0V2FPT0WU
U-87-MG Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XsNmlEPTB;Mz6wN|UyOyEQvF2= NYrhVmxmW0GQR1XS
NCI-H747 M{DvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnMTWM2OD1|LkC1NlA3KM7:TR?= MVvTRW5ITVJ?
CTB-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLoXWJiUUN3ME2zMlA2Ozd4IN88US=> NHS1U4VUSU6JRWK=
RPMI-8226 NEfyfVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwMUSzO|gh|ryP MnLuV2FPT0WU
NCI-H2141 NYDuXGJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTEVmZSUUN3ME2zMlE3PTZ4IN88US=> NXPX[op1W0GQR1XS
IST-MES1 NYfUR|g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyyTWM2OD1|LkG4Nlc6KM7:TR?= MWnTRW5ITVJ?
TE-5 NH\NO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly3TWM2OD1|LkKxN|QzKM7:TR?= NXjtTnpFW0GQR1XS
UACC-257 NVzmNnhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTNwNEO2OVkh|ryP NVH5cog2W0GQR1XS
SK-N-FI M3Pz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OzOmlEPTB;Mz60OVIzPyEQvF2= MVPTRW5ITVJ?
MFH-ino MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTNwNE[1PFkh|ryP MnfoV2FPT0WU
SF268 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4KxR2lEPTB;Mz60PFE4PCEQvF2= M4nxbnNCVkeHUh?=
TE-12 NYH3OpdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHoS4F3UUN3ME2zMlUyPjl7IN88US=> M1fJWHNCVkeHUh?=
NB6 MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTNwNUW1OlMh|ryP NGmy[ZJUSU6JRWK=
DJM-1 M1Hobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIcldKSzVyPUOuOVk5QTlizszN NIHZelhUSU6JRWK=
MZ1-PC NWDOZmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LvdWlEPTB;Mz62NVYzPCEQvF2= NEXJd5hUSU6JRWK=
OCI-AML2 Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjyb2luUUN3ME2zMlYzPjdzIN88US=> NHHtZYxUSU6JRWK=
NCI-H1155 MkCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:2eHlKSzVyPUOuO|A6PDdizszN NYS3T5hGW0GQR1XS
RKO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTNwN{exPFkh|ryP NXPySVJtW0GQR1XS
ECC4 NITtUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHmTpBKSzVyPUOuPVcyQTVizszN MX\TRW5ITVJ?
BB65-RCC Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTNwOUe1OFch|ryP NVe3bYNVW0GQR1XS
EB-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2iyc2lEPTB;Mz65PVY{OyEQvF2= MUTTRW5ITVJ?
SHP-77 NU\MOZMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjGTI5kUUN3ME20MlAxPTJ2IN88US=> NXmxWJp3W0GQR1XS
NCI-H2196 NWDmR2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;l[FJKSzVyPUSuNFU3OjVizszN NHT0Oo1USU6JRWK=
GI-ME-N MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwME[zPVkh|ryP NUe5UHhpW0GQR1XS
MN-60 M2SxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTpXIxKSzVyPUSuNVA5PyEQvF2= M1fudHNCVkeHUh?=
NCI-H1694 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3O0TWlEPTB;ND6xN|QxPSEQvF2= M{ntPXNCVkeHUh?=
LU-65 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\ydIxOUUN3ME20MlE2OzN{IN88US=> MULTRW5ITVJ?
NCI-H1436 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTRwMUizN|Mh|ryP MnjiV2FPT0WU
KINGS-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7wPWptUUN3ME20MlMyPDN{IN88US=> NV;xSmg4W0GQR1XS
GT3TKB NIPaepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TLRmlEPTB;ND6zN|I3QCEQvF2= M3faT3NCVkeHUh?=
Becker Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W0NmlEPTB;ND6zO|MyOiEQvF2= M322[nNCVkeHUh?=
HCC1187 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwOEm2OVch|ryP NH3MRXlUSU6JRWK=
D-502MG NFjoeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DXT2lEPTB;NT6wNFQyPiEQvF2= M1f1SnNCVkeHUh?=
VA-ES-BJ M{XFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz5TWM2OD13LkGzO|c5KM7:TR?= MWXTRW5ITVJ?
NB7 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\1Sm1{UUN3ME21MlE1OTF{IN88US=> MoH1V2FPT0WU
SW962 NEfJc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD13LkO4PFE1KM7:TR?= Mon0V2FPT0WU
no-11 NV:wZ3F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DHSGlEPTB;NT63OlM1OyEQvF2= M3zHTXNCVkeHUh?=
KNS-81-FD MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTVwOUC2PVQh|ryP Mnq1V2FPT0WU
COLO-684 NFHk[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF6wepRKSzVyPUWuPVk1QTRizszN MV3TRW5ITVJ?
D-263MG NW\BTFRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTZwMEi4PVUh|ryP MoTVV2FPT0WU
EW-24 NGHrVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTZwMki1NUDPxE1? NVf0cIVxW0GQR1XS
TE-10 NIPmXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILiNJlKSzVyPU[uOFI3OjNizszN MXjTRW5ITVJ?
EKVX NETxXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LScGlEPTB;Nj60OlMzOSEQvF2= MUjTRW5ITVJ?
NCI-H1648 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z5NGlEPTB;Nj62O|U2PyEQvF2= NIHQVlRUSU6JRWK=
LB771-HNC NWDH[JVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6ZoZ{UUN3ME22MlkzOzBzIN88US=> MnX2V2FPT0WU
SK-MEL-1 M4rEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2G0SWlEPTB;OD6xN|E3PiEQvF2= M37aSHNCVkeHUh?=
COLO-668 NGTSUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrXTWM2OD16LkK3O|g3KM7:TR?= NXzxRnpVW0GQR1XS
EW-12 M{DD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXkVpI2UUN3ME24MlQxQDB|IN88US=> MX3TRW5ITVJ?
A253 NVnrNXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1X6cWlEPTB;OD64OFY3OSEQvF2= Ml\YV2FPT0WU
NCI-H2126 NHjl[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnz[VFvUUN3ME24Mlg6OzF7IN88US=> NXHJb45DW0GQR1XS
Calu-6 NELvcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoW0TWM2OD16Lkm5NFQzKM7:TR?= NFPrcYZUSU6JRWK=
NCI-H23 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLHTWM2OD17LkG3O|Q3KM7:TR?= M1fhO3NCVkeHUh?=
WSU-NHL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlwN{e0O|gh|ryP MV\TRW5ITVJ?
MMAC-SF NVqxR2Z6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTlwOUe5NFQh|ryP M2TUPXNCVkeHUh?=
SK-LMS-1 M1KxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFyLkK4N|Qh|ryP MX\TRW5ITVJ?
GCIY NYD6RYQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LKcWlEPTB;MUCuOVkzPCEQvF2= M1j6SHNCVkeHUh?=
TE-15 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTFzLk[wNFQh|ryP M3HIWnNCVkeHUh?=
EoL-1-cell NGriZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1W2e2lEPTB;MUGuO|Y5OiEQvF2= NVHrZnM6W0GQR1XS
NCI-H2081 NEK4XYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFzLke3PFYh|ryP NHvoemtUSU6JRWK=
EW-3 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTmTWM2OD1zMj6yOFY{KM7:TR?= NG\WZlBUSU6JRWK=
CAS-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTF{LkO2N|Eh|ryP MlrvV2FPT0WU
C2BBe1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\R[2lEPTB;MUKuOlE{OSEQvF2= Mne0V2FPT0WU
D-247MG NXj0S|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkT5TWM2OD1zMj63PVUzKM7:TR?= NWDCWm1XW0GQR1XS
NCI-SNU-5 M33lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHkfGFvUUN3ME2xNk45ODF|IN88US=> NY\HPIUyW0GQR1XS
LS-1034 NX\tRYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XZdWlEPTB;MUSuN|k4PSEQvF2= NUD4OFBtW0GQR1XS
EW-18 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwfmVKSzVyPUG0MlQ1QCEQvF2= M3HFbHNCVkeHUh?=
Raji NGO1O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zNb2lEPTB;MUSuOVA1QSEQvF2= MXTTRW5ITVJ?
D-283MED NX[zPVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37VS2lEPTB;MUSuOlI4OSEQvF2= M3jacnNCVkeHUh?=
MZ2-MEL NVmyZXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXLTWM2OD1zND65Olk3KM7:TR?= M{nWVnNCVkeHUh?=
NCI-SNU-16 M2jDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzWcGpKSzVyPUG1MlQ3OzNizszN M3;BZnNCVkeHUh?=
P30-OHK NF7XV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnUN3hKSzVyPUG3Mlc5OzFizszN Mm[1V2FPT0WU
RXF393 NFLwR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF7LkCxPFYh|ryP M4PydXNCVkeHUh?=
NCI-H1395 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfQTWM2OD1{MD62O|A{KM7:TR?= MYfTRW5ITVJ?
U-698-M MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKbGlEPTB;MkCuO|A4PSEQvF2= M1PxRnNCVkeHUh?=
NCI-SNU-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XYTWlEPTB;MkCuO|IzOyEQvF2= MljGV2FPT0WU
SW684 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nEb2lEPTB;MkGuNVcyPiEQvF2= MnvEV2FPT0WU
NCI-H716 NGPyRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPTfZpxUUN3ME2yNU4{OTV2IN88US=> MYjTRW5ITVJ?
JVM-2 NIjjXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\sO4hKSzVyPUKxMlQyOzNizszN NX3ndYVmW0GQR1XS
NCI-H1581 NFO2dJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrlZ2hKSzVyPUKyMlQyPDhizszN MlXOV2FPT0WU
CA46 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjKXpZKSzVyPUOxMlY6OzZizszN M1vKNnNCVkeHUh?=
SNB75 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn5Z|hKSzVyPUOzMlY2ODNizszN M1v0TXNCVkeHUh?=
KNS-42 NFHleopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHwN5ZIUUN3ME2zOU46PjJ2IN88US=> MlHJV2FPT0WU
TUR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTN4LkC1NlEh|ryP M{HNbnNCVkeHUh?=
REH NEjHfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnQTWM2OD1|Nz64NlEyKM7:TR?= MmjGV2FPT0WU
EW-22 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLlTWM2OD12Mj6yPFg2KM7:TR?= MVvTRW5ITVJ?
NCI-H446 M1KxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\TcoVQUUN3ME20Nk44QDV|IN88US=> M2fZR3NCVkeHUh?=
ES3 NUX3WlM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLrTWM2OD12Mz6xN|M6KM7:TR?= NVHkPGFkW0GQR1XS
EW-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;ON2lEPTB;NESuPFIyQCEQvF2= MkDYV2FPT0WU
RH-1 NYDKZlZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlq1TWM2OD12Nz61PFEzKM7:TR?= M1HuOHNCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

+ 展開

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

+ 展開
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 製剤: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から右までの手順で、溶剤を製品に加えることです:
2% DMSO+30% PEG 300
10mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
保管
別名 SNDX-275

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

Related Antibodies

HDAC信号経路図

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID